Salvat Laboratories announced data showing its corticosteroid SVT-15473 clobetasol 0.05% ophthalmic nanoemulsion was effective and safe for reducing inflammation and pain after eye surgery. Information presented at the recent Association for Research in Vision and Ophthalmology (ARVO) meeting included pooled data from 2 successful phase 3 trial in more than 400 patients. IMPACT-SVT is a patented nanoemulsion drug-delivery technology that the company said improves drug penetration and bioadhesion allowing a “superpotent” corticosteroid to be used as topical drops. The study drug had a limited impact on IOP and offers advantages in terms of ocular surface coverage and absorption. The company noted that there is no blurred vision or discomfort after application. After a standard 14-day course of treatment, the therapy has proven to have no rebound effect in the following 2 weeks, thereby eliminating the need for a taper.